ArticleThe Journal of clinical investigation1997
Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.
Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 189 citations in OpenAlex.
- Dual-Specificity Phosphatase 6 Deficiency Attenuates Arterial-Injury-Induced Intimal Hyperplasia in Mice.International journal of molecular sciences · 2023Article
- FAK in the nucleus prevents VSMC proliferation by promoting p27 and p21 expression via Skp2 degradation.Cardiovascular research · 2022Article
- Role of PCK2 in the proliferation of vascular smooth muscle cells in neointimal hyperplasia.International journal of biological sciences · 2022Article
- Deletion of the FHL2 gene attenuates intima-media thickening in a partially ligated carotid artery ligated mouse model.Journal of cellular and molecular medicine · 2020Article
- Review
- Poldip2 knockdown inhibits vascular smooth muscle proliferation and neointima formation by regulating the expression of PCNA and p21.Laboratory investigation; a journal of technical methods and pathology · 2019Article
- Application of galangin, an active component of Alpinia officinarum Hance (Zingiberaceae), for use in drug-eluting stents.Scientific reports · 2017Article
- Cell-cycle arrest in mature adipocytes impairs BAT development but not WAT browning, and reduces adaptive thermogenesis in mice.Scientific reports · 2017Article
- The role of sex steroid hormones in the pathophysiology and treatment of sarcopenia.Osteoporosis and sarcopenia · 2016Review
- The COP9 signalosome and vascular function: intriguing possibilities?American journal of cardiovascular disease · 2015Review
- A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.The Journal of clinical investigation · 2014Article
- Mixed-lineage kinase 3 deficiency promotes neointima formation through increased activation of the RhoA pathway in vascular smooth muscle cells.Arteriosclerosis, thrombosis, and vascular biology · 2014Article
- Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.Theranostics · 2014Review
- Dysregulation of the Mammalian Target of Rapamycin and p27Kip1 Promotes Intimal Hyperplasia in Diabetes Mellitus.Pharmaceuticals (Basel, Switzerland) · 2013Article
- A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts.Journal of vascular surgery · 2013Article
- Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors.Ochsner journal · 2013Article
- AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells.Circulation research · 2011Article
- The multifunctional Ca2+/calmodulin-dependent kinase II delta (CaMKIIdelta) controls neointima formation after carotid ligation and vascular smooth muscle cell proliferation through cell cycle regulation by p21.The Journal of biological chemistry · 2011Article
- Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice.Biochemical and biophysical research communications · 2010Article
- Augmented cell cycle protein expression and kinase activity in atherosclerotic rabbit vessels.Experimental and clinical cardiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormal proliferation of vascular smooth muscle cells (VSMCs) contributes to intimal hyperplasia during atherosclerosis and restenosis, but the endogenous cell cycle regulatory factors underlying VSMC growth in response to arterial injury are not well understood. In the present study, we report that downregulation of cyclin-dependent kinase 2 (cdk2) activity in serum-deprived VSMCs was associated with the formation of complexes between cdk2 and its inhibitory protein p27(KIP1) (p27). Ectopic overexpression of p27 in serum-stimulated VSMCs resulted in the inhibition of cdk2 activity and repression of cyclin A promoter activity. Collectively, these findings indicate that p27 may contribute to VSMC growth arrest in vitro. Using the rat carotid model of balloon angioplasty, a marked upregulation of p27 was observed in injured arteries. High levels of p27 expression in the media and neointima correlated with downregulation of cdk2 activity at 2 wk after angioplasty, and adenovirus-mediated overexpression of p27 in balloon-injured arteries attenuated neointimal lesion formation. Thus, the inhibition of cdk2 function and repression of cyclin A gene transcription through the induction of the endogenous p27 protein provides a mechanism for the inhibition of VSMC growth at late time points after angioplasty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.